HEXO Stock Price Target and Analyst Ratings (NYSE:HEXO)

Analyst Price Target for HEXO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$1.95

▼ -70.25% Downside Potential

This price target is based on 16 analysts offering 12 month price targets for HEXO in the last 3 months. The average price target is $1.95, with a high forecast of $8.00 and a low forecast of $0.75. The average price target represents a -70.25% upside from the last price of $6.54.

Hold

The current consensus among 16 polled investment analysts is to hold stock in HEXO. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
1 buy ratings
4 hold ratings
3 sell ratings

Ratings as of

9/11/2019

0 strong buy ratings
2 buy ratings
7 hold ratings
4 sell ratings

Ratings as of

12/10/2019

0 strong buy ratings
3 buy ratings
7 hold ratings
6 sell ratings

Ratings as of

3/9/2020

0 strong buy ratings
3 buy ratings
8 hold ratings
7 sell ratings

Ratings as of

6/7/2020

0 strong buy ratings
3 buy ratings
8 hold ratings
8 sell ratings

Ratings as of

9/5/2020

0 strong buy ratings
3 buy ratings
6 hold ratings
7 sell ratings

Ratings as of

12/4/2020

0 strong buy ratings
3 buy ratings
7 hold ratings
6 sell ratings

Ratings as of

2/2/2021

0 strong buy ratings
3 buy ratings
7 hold ratings
6 sell ratings

Ratings as of

3/4/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/18/2021	Canaccord Genuity	Boost Price Target	Buy	$5.00 ➝ $8.00	High	i
2/17/2021	CIBC	Upgrade	Neutral ➝ Sector Outperform		Low	i
2/4/2021	Stifel Nicolaus	Reiterated Rating	Sell	$3.40	Medium	i
1/26/2021	Stifel Nicolaus	Reiterated Rating	Buy		High	i
12/16/2020	Stifel Nicolaus	Upgrade	Sell ➝ Hold	$0.60 ➝ $1.40	High	i
12/15/2020	Canaccord Genuity	Boost Price Target	Hold	$1.00 ➝ $1.25	High	i
12/14/2020	Atb Cap Markets	Upgrade	Underperform ➝ Sector Perform		High	i Rating by D. Kideckel at Atb Cap Markets
11/2/2020	Canaccord Genuity	Lower Price Target	Hold	$1.50 ➝ $1.00	Medium	i
11/2/2020	Stifel Nicolaus	Lower Price Target	Sell	$0.90 ➝ $0.60	Medium	i
9/16/2020	Jefferies Financial Group	Reiterated Rating	Sell	$0.75	Medium	i
8/18/2020	CIBC	Lower Price Target	Underperform	$1.00 ➝ $0.90	Low	i
7/22/2020	Cantor Fitzgerald	Upgrade	Underweight ➝ Neutral	$1.25	High	i Rating by P. Zuanic at Cantor Fitzgerald
7/1/2020	Bryan, Garnier & Co	Downgrade	Buy ➝ Sell		Medium	i
6/29/2020	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$1.30	Medium	i Rating by Tamy Chen at BMO Capital Markets
6/12/2020	MKM Partners	Reiterated Rating	Hold	$1.10	Low	i Rating by William Kirk at MKM Partners
6/12/2020	Canaccord Genuity	Reiterated Rating	Hold	$1.50	Medium	i
6/11/2020	Oppenheimer	Reiterated Rating	Hold		High	i
6/1/2020	Alliance Global Partners	Reiterated Rating	Buy		High	i Rating by A. Grey at Alliance Global Partners
4/15/2020	Alliance Global Partners	Lower Price Target	Buy	$2.50 ➝ $1.50	Low	i
3/31/2020	MKM Partners	Reiterated Rating	Hold	$1.00	High	i Rating by William Kirk at MKM Partners
3/31/2020	Bank of America	Initiated Coverage	Underperform		High	i
3/31/2020	Roth Capital	Lower Price Target	Neutral	$1.30 ➝ $1.00	Medium	i Rating by S. Fortune at Roth Capital
3/31/2020	Citigroup	Initiated Coverage	Underperform	$1.00	High	i
3/31/2020	Desjardins	Downgrade	Buy ➝ Hold		High	i
3/18/2020	AltaCorp Capital	Downgrade	Sector Perform ➝ Underperform	$3.15 ➝ $1.20	High	i Rating by D. Kideckel at AltaCorp Capital
3/18/2020	BMO Capital Markets	Downgrade	Market Perform ➝ Underperform		High	i
3/9/2020	Stifel Nicolaus	Initiated Coverage	Sell	$1.15	Medium	i Rating by W. Andrew Carter at Stifel Nicolaus
3/2/2020	Alliance Global Partners	Initiated Coverage	Buy		Low	i
2/21/2020	Jefferies Financial Group	Downgrade	Hold ➝ Underperform	$1.00	Low	i Rating by Owen Bennett at Jefferies Financial Group Inc.
1/28/2020	MKM Partners	Downgrade	Buy ➝ Neutral	$1.50	Medium	i
1/17/2020	Roth Capital	Lower Price Target	Neutral	$2.25 ➝ $1.75	Low	i Rating by S. Fortune at Roth Capital
12/16/2019	Pi Financial	Downgrade	Sell	$2.00	High	i Rating by Devin Schilling at Pi Financial
12/13/2019	Cantor Fitzgerald	Reiterated Rating	Sell	$1.82	High	i Rating by Pablo Zuanic at Cantor Fitzgerald
11/5/2019	Cantor Fitzgerald	Initiated Coverage	Underweight		Low	i Rating by P. Zuanic at Cantor Fitzgerald
10/30/2019	Eight Capital	Downgrade	Neutral ➝ Sell		Low	i
10/30/2019	Canaccord Genuity	Downgrade	Buy ➝ Hold		Low	i
10/29/2019	AltaCorp Capital	Downgrade	Outperform ➝ Sector Perform		High	i Rating by D. Kideckel at AltaCorp Capital
10/29/2019	Roth Capital	Lower Price Target	Neutral	$3.00 ➝ $2.50	Low	i Rating by S. Fortune at Roth Capital
10/25/2019	CIBC	Downgrade	Neutral ➝ Sector Underperform	$4.00 ➝ $3.00	Low	i Rating by John Zamparo at CIBC
10/21/2019	CIBC	Reiterated Rating	Hold	$4.00	Medium	i
10/14/2019	Seaport Global Securities	Downgrade	Buy ➝ Neutral		High	i Rating by B. Hundley at Seaport Global Securities
10/11/2019	Roth Capital	Downgrade	Buy ➝ Neutral	$3.00	High	i Rating by S. Fortune at Roth Capital
10/11/2019	Jefferies Financial Group	Upgrade	Underperform ➝ Hold		High	i
10/10/2019	Beacon Securities	Downgrade	Buy ➝ Hold		High	i Rating by R. Stanley at Beacon Securities
10/7/2019	Bank of America	Downgrade	Buy ➝ Underperform	$9.00 ➝ $4.00	Medium	i Rating by Christopher Carey at Bank of America Co.
9/20/2019	MKM Partners	Initiated Coverage	Buy	$12.00	High	i
6/25/2019	CIBC	Reiterated Rating	Outperform ➝ Market Perform		Medium	i
6/25/2019	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Medium	i
6/14/2019	CIBC	Downgrade	Sector Outperform ➝ Neutral		Low	i
6/13/2019	Bank of America	Set Price Target	Buy	$10.00	High	i Rating by Christopher Carey at Bank of America Co.
4/25/2019	Desjardins	Initiated Coverage	Buy ➝ Buy	$7.17	High	i Rating by J. Chu at Desjardins
4/17/2019	Bank of America	Initiated Coverage	Buy ➝ Buy		High	i
4/4/2019	AltaCorp Capital	Reiterated Rating	Outperform		High	i Rating by D. Kideckel at AltaCorp Capital
2/25/2019	Jefferies Financial Group	Initiated Coverage	Underperform ➝ Underperform		Low	i
2/21/2019	Seaport Global Securities	Reiterated Rating	Buy		N/A	i Rating by B. Hundley at Seaport Global Securities
2/21/2019	Seaport Global Securities	Initiated Coverage	Buy ➝ Buy	$12.00	High	i Rating by B. Hundley at Seaport Global Securities
2/19/2019	Beacon Securities	Reiterated Rating	Buy		High	i Rating by R. Stanley at Beacon Securities
2/19/2019	Oppenheimer	Initiated Coverage	Outperform	$7.00	High	i
2/19/2019	CIBC	Initiated Coverage	Outperform ➝ Outperform	$7.00	High	i

(Data available from 3/4/2016 forward)

HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. It offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. The company offers its adult-use and medical products under the HEXO brand name. Additionally, it offers cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brand; and cannabis products under Original Stash and Up brand names. The company was formerly known as The Hydropothecary Corporation and changes its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Kanata, Canada.

Today's Range

Now: $6.54

$6.25

$7.01

50 Day Range

MA: $7.34

$5.35

$10.28

52 Week Range

Now: $6.54

$1.38

$11.04

Volume

417,772 shs

Average Volume

9,163,887 shs

Market Capitalization

$798.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41

Frequently Asked Questions

What sell-side analysts currently cover shares of HEXO?

The following sell-side analysts have issued reports on HEXO in the last twelve months: Alliance Global Partners, AltaCorp Capital, Atb Cap Markets, Bank of America Co., BMO Capital Markets, Bryan, Garnier & Co, Canaccord Genuity, Cantor Fitzgerald, CIBC, Citigroup Inc., Desjardins, Jefferies Financial Group Inc., MKM Partners, Oppenheimer Holdings Inc., Roth Capital, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for HEXO.

What is the current price target for HEXO?

11 Wall Street analysts have set twelve-month price targets for HEXO in the last year. Their average twelve-month price target is $1.95, suggesting a possible downside of 69.7%. Canaccord Genuity has the highest price target set, predicting HEXO will reach $8.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $0.75 for HEXO in the next year.
View the latest price targets for HEXO.

What is the current consensus analyst rating for HEXO?

HEXO currently has 6 sell ratings, 7 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HEXO, but not buy more shares or sell existing shares.
View the latest ratings for HEXO.

What other companies compete with HEXO?

Other companies that are similar to HEXO include USANA Health Sciences, Aurora Cannabis, Sundial Growers, ChromaDex, Canopy Rivers, Charlie's, MediWound, Natural Alternatives International, Nutra Pharma, Glucose Health, Happiness Biotech Group, True Drinks, Mannatech, FSD Pharma and Tauriga Sciences.

How do I contact HEXO's investor relations team?

The company's listed phone number is 844-406-1852 and its investor relations email address is [email protected] The official website for HEXO is www.hexocorp.com.

NYSE:HEXO - HEXO Stock Price Target and Predictions

Analyst Price Target for HEXO

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of HEXO?

What is the current price target for HEXO?

What is the current consensus analyst rating for HEXO?

What other companies compete with HEXO?

How do I contact HEXO's investor relations team?